244 related articles for article (PubMed ID: 23354319)
1. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
3. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
4. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma.
Chuang FH; Hsue SS; Wu CW; Chen YK
J Oral Pathol Med; 2009 Nov; 38(10):753-8. PubMed ID: 19566744
[TBL] [Abstract][Full Text] [Related]
6. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.
Russmueller G; Moser D; Würger T; Wrba F; Christopoulos P; Kostakis G; Seemann R; Stadler V; Wimmer G; Kornek G; Psyrri A; Filipits M; Perisanidis C
Oral Oncol; 2015 Mar; 51(3):247-53. PubMed ID: 25532817
[TBL] [Abstract][Full Text] [Related]
9. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
[TBL] [Abstract][Full Text] [Related]
11. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
12. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
13. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
14. The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma.
Jimi E; Furuta H; Matsuo K; Tominaga K; Takahashi T; Nakanishi O
Oral Dis; 2011 Jul; 17(5):462-8. PubMed ID: 21496184
[TBL] [Abstract][Full Text] [Related]
15. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Wang J; Chen TY; Qin S; Duan Y; Wang G
Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
[TBL] [Abstract][Full Text] [Related]
17. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
18. [The participation of RANK, RANKL and OPG in tumor osteolysis].
Stanisławowski M; Kmieć Z
Postepy Hig Med Dosw (Online); 2009 May; 63():234-41. PubMed ID: 19502684
[TBL] [Abstract][Full Text] [Related]
19. [Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor].
Kushlinskiĭ NE; Timofeev IuS; Gershteĭn ES; Solov'ev IuN
Vopr Onkol; 2014; 60(4):413-21. PubMed ID: 25552059
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo.
Furuta H; Osawa K; Shin M; Ishikawa A; Matsuo K; Khan M; Aoki K; Ohya K; Okamoto M; Tominaga K; Takahashi T; Nakanishi O; Jimi E
Int J Cancer; 2012 Sep; 131(5):E625-35. PubMed ID: 22262470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
